NEW YORK (GenomeWeb News) – Roche NimbleGen said today that it has aligned its chromatin immunoprecipitation-on-microarrays (ChIP-chip) with Sigma Aldrich's GenomePlex whole-genome amplification technology, and the companies will co-market the technologies together.
Researchers can use the two platforms together to study the genome for epigenetic interactions between DNA and DNA-binding proteins to find out what regions are transcriptionally active or repressed, and the mechanisms that regulate these processes, Roche said.
The companies plan to publish protocols for ChIP-chip research and will provide technical support to assist researchers integrating the two platforms, and each company will co-market the products together.
The firms did not disclose financial or other terms of the alliance.